These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28790114)

  • 1. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors.
    Dhawan MS; Bartelink IH; Aggarwal RR; Leng J; Zhang JZ; Pawlowska N; Terranova-Barberio M; Grabowsky JA; Gewitz A; Chien AJ; Moasser M; Kelley RK; Maktabi T; Thomas S; Munster PN
    Clin Cancer Res; 2017 Nov; 23(21):6400-6410. PubMed ID: 28790114
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
    de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
    Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    Lee JM; Peer CJ; Yu M; Amable L; Gordon N; Annunziata CM; Houston N; Goey AK; Sissung TM; Parker B; Minasian L; Chiou VL; Murphy RF; Widemann BC; Figg WD; Kohn EC
    Clin Cancer Res; 2017 Mar; 23(6):1397-1406. PubMed ID: 27663600
    [No Abstract]   [Full Text] [Related]  

  • 4. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
    Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
    Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
    [No Abstract]   [Full Text] [Related]  

  • 7. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
    Lee JM; Hays JL; Annunziata CM; Noonan AM; Minasian L; Zujewski JA; Yu M; Gordon N; Ji J; Sissung TM; Figg WD; Azad N; Wood BJ; Doroshow J; Kohn EC
    J Natl Cancer Inst; 2014 Jun; 106(6):dju089. PubMed ID: 24842883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
    Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
    Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
    Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
    Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
    [No Abstract]   [Full Text] [Related]  

  • 13. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
    van der Noll R; Jager A; Ang JE; Marchetti S; Mergui-Roelvink MWJ; Lolkema MP; de Jonge MJA; van der Biessen DA; Brunetto AT; Arkenau HT; Tchakov I; Beijnen JH; de Bono JS; Schellens JHM
    Invest New Drugs; 2020 Aug; 38(4):1117-1128. PubMed ID: 31667659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
    Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
    Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
    Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
    Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
    Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
    [No Abstract]   [Full Text] [Related]  

  • 19. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
    Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
    Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
    Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.